Pharmacological evaluation of synthetic galloyl catechin analogues with anti-staphylococcal properties

具有抗葡萄球菌特性的合成没食子酰儿茶素类似物的药理学评价

基本信息

  • 批准号:
    G0801757/1
  • 负责人:
  • 金额:
    $ 66.59万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2009
  • 资助国家:
    英国
  • 起止时间:
    2009 至 无数据
  • 项目状态:
    已结题

项目摘要

Antibiotics are among the most beneficial drugs ever introduced but their use is compromised by the emergence and spread of antibiotic resistant bacteria. The need for new treatments for infection has never been greater but society has been slow to respond and we are now facing a situation where superbugs such as MRSA frequently cause difficult-to-treat, life-threatening infections and where colonisation of our hospitals by these bacteria is increasingly likely to result in the cancellation of major surgery. The problem is of worldwide importance and, in the USA, MRSA now kills more patients than the AIDS virus. We have been researching ways to reverse antibiotic resistance in MRSA, making it again sensitive to inexpensive antibiotics such as methicillin and oxacillin. These antibiotics prevent bacteria from making the rigid cell wall that they need to survive; MRSA subverts this action by altering the way it makes its wall. We have found that a constituent of Japanese green tea called epicatechin gallate, or ECg, interferes with the MRSA-subverting machinery and converts the bacteria to methicillin sensitivity. We investigated the main target for ECg in MRSA and obtained strong evidence that it exerts its resistance modifying effect by binding to the MRSA membrane. MRSA and other staphylococci are dangerous pathogens because, not only are they resistant to our best antibiotics, they also excrete a range of toxins that can damage the host, cause symptoms of disease and circumvent the bodys immune defences. These proteins must be transported across the membrane and out of the cell in order to damage the patient: we have found that ECg prevents this transport process, effectively disarming the pathogen and raising the possibility that it could be used as a therapeutic in its own right. Unfortunately, ECg has a number of properties that could prevent its therapeutic use - it is broken down to inactive compounds in the body and its potency is only moderate - but we have designed ways to engineer the molecule to improve its attraction as a drug. We therefore propose to enhance the potential of ECg through rational design and chemical synthesis of novel analogues and to determine their properties in the laboratory and in models of infection. We hope that these studies will enable us to incorporate key design features into a new drug candidate that we can take forward to the next stage of development.
抗生素是有史以来最有益的药物之一,但它们的使用受到抗生素耐药性细菌的出现和传播的影响。对新的感染治疗方法的需求从未如此之大,但社会反应缓慢,我们现在面临的情况是,MRSA等超级细菌经常导致难以治疗,危及生命的感染,这些细菌在我们医院的定植越来越有可能导致取消大手术。这个问题是世界性的重要性,在美国,MRSA现在比艾滋病病毒杀死更多的病人。我们一直在研究逆转MRSA抗生素耐药性的方法,使其再次对甲氧西林和苯唑西林等廉价抗生素敏感。这些抗生素阻止细菌制造它们生存所需的刚性细胞壁; MRSA通过改变其制造细胞壁的方式来破坏这种行为。我们发现,日本绿色茶中一种名为表儿茶素没食子酸酯(epicatechin gallate,简称ECG)的成分会干扰MRSA破坏机制,并将细菌转化为甲氧西林敏感性。我们研究了ECg在MRSA中的主要靶点,并获得了强有力的证据表明它通过与MRSA膜结合而发挥其耐药性修饰作用。MRSA和其他葡萄球菌是危险的病原体,因为它们不仅对我们最好的抗生素有抗药性,而且还分泌一系列毒素,这些毒素会损害宿主,引起疾病症状,并绕过身体的免疫防御。这些蛋白质必须穿过细胞膜运输到细胞外才能损害患者:我们发现ECG可以阻止这种运输过程,有效地解除病原体的武装,并提高了它本身可用作治疗的可能性。不幸的是,心电图具有许多特性,可能会阻止其治疗用途-它在体内被分解为非活性化合物,其效力仅为中等-但我们已经设计了设计分子的方法,以提高其作为药物的吸引力。因此,我们建议通过合理的设计和化学合成的新型类似物,以提高心电图的潜力,并确定其性质在实验室和感染模型。我们希望这些研究将使我们能够将关键的设计特征融入到我们可以进入下一个开发阶段的新药候选中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter Taylor其他文献

Evaluation of joint activation and joint spacing in concrete overlays
混凝土覆盖层接缝激活和接缝间距的评估
  • DOI:
    10.1080/14680629.2021.2005669
  • 发表时间:
    2021-11
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Yu-an Chen;Peter Taylor;Halil Ceylan;Xuhao Wang
  • 通讯作者:
    Xuhao Wang
The Spirit Level: Why More Equal Societies Almost Always Do Better
  • DOI:
    10.1080/13606710903141476
  • 发表时间:
    2009-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Peter Taylor
  • 通讯作者:
    Peter Taylor
公共スポーツ施設の管理運営制度に関する研究
公共体育设施管理运营体系研究
Accelerating transitions? Planning for decarbonisation in local and regional energy systems
  • DOI:
    10.1016/j.erss.2024.103875
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Helen Poulter;Jess Britton;Imogen Rattle;Ronan Bolton;Jan Webb;Peter Taylor
  • 通讯作者:
    Peter Taylor
Correction: Quantifying beta cell function in the preclinical stages of type 1 diabetes
  • DOI:
    10.1007/s00125-024-06335-w
  • 发表时间:
    2024-11-27
  • 期刊:
  • 影响因子:
    10.200
  • 作者:
    Alfonso Galderisi;Alice L. J. Carr;Mariangela Martino;Peter Taylor;Peter Senior;Colin Dayan
  • 通讯作者:
    Colin Dayan

Peter Taylor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter Taylor', 18)}}的其他基金

[SurgeryNet] Epilepsy surgery induced brain network changes: relation to patient outcomes
[SurgeryNet] 癫痫手术引起的脑网络变化:与患者预后的关系
  • 批准号:
    MR/T04294X/1
  • 财政年份:
    2021
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Fellowship
Biocatalytic Approaches to the Synthetic Manipulation of Silicones
有机硅合成操作的生物催化方法
  • 批准号:
    EP/S013660/1
  • 财政年份:
    2019
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Molecular mechanisms of enterobacterial resistance to complement
肠杆菌补体耐药的分子机制
  • 批准号:
    MR/R009937/1
  • 财政年份:
    2018
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Treatment of multi-drug-resistant Gram-negative bacterial infections using capsule depolymerases
使用胶囊解聚酶治疗多重耐药革兰氏阴性细菌感染
  • 批准号:
    MR/N012542/1
  • 财政年份:
    2016
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Consortium for Modelling and Analysis of Decentralised Energy Storage (C-MADEnS)
去中心化储能建模与分析联盟 (C-MADenS)
  • 批准号:
    EP/N001745/1
  • 财政年份:
    2015
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Modulation of innate defences in the neonatal gastrointestinal tract by colonizing neuropathogenic Escherichia coli
通过定植神经病原性大肠杆菌来调节新生儿胃肠道的先天防御
  • 批准号:
    MR/K018396/1
  • 财政年份:
    2013
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Disruption of cytoplasmic membrane-associated functions in Staphylococcus aureus by epicatechin gallate
表儿茶素没食子酸酯破坏金黄色葡萄球菌细胞质膜相关功能
  • 批准号:
    BB/I005579/1
  • 财政年份:
    2011
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Modulation of beta-lactam resistance in methicillin-resistant Staphylococcus aureus by catechin gallates
儿茶素没食子酸酯对耐甲氧西林金黄色葡萄球菌的β-内酰胺耐药性的调节
  • 批准号:
    G0600004/1
  • 财政年份:
    2007
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
Qualification of ultrasonography as a biomarker of prognosis and response to therapy in rheumatoid arthritis
超声检查作为类风湿关节炎预后和治疗反应生物标志物的资格
  • 批准号:
    G0601962/1
  • 财政年份:
    2007
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Research Grant
The Implications of Heterogeneity for the Philosophy, History, Sociology, and Science of Biological Determinism
异质性对生物决定论的哲学、历史、社会学和科学的影响
  • 批准号:
    0634744
  • 财政年份:
    2006
  • 资助金额:
    $ 66.59万
  • 项目类别:
    Continuing Grant

相似国自然基金

基于重要农地保护LESA(Land Evaluation and Site Assessment)体系思想的高标准基本农田建设研究
  • 批准号:
    41340011
  • 批准年份:
    2013
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
基于观测角度的汉语名词性隐喻逻辑释义和评价方法研究
  • 批准号:
    61075058
  • 批准年份:
    2010
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目
面向认知网络的自律计算模型及评价方法研究
  • 批准号:
    60973027
  • 批准年份:
    2009
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

ALTERING THE IMMUNE LANDSCAPE TO AUGMENT BONE REGENERATION
改变免疫景观以增强骨再生
  • 批准号:
    10727797
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Synthetic Scavenger Medical Countermeasures for Fentanyl
芬太尼的合成清除剂医疗对策
  • 批准号:
    10726539
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Cannabinoid type 2 receptors as a therapeutic target for substance use disorders
大麻素 2 型受体作为物质使用障碍的治疗靶点
  • 批准号:
    10606224
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biology
使用无细胞合成生物学对细胞外囊泡模拟物进行自下而上的高通量原型设计
  • 批准号:
    10638114
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Synthetic circuits for therapeutic platelet production and immunomodulation
用于治疗性血小板生成和免疫调节的合成回路
  • 批准号:
    10745237
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Mechanism and Countermeasure of Carfentanil-induced Respiratory Disorder and Death
卡芬太尼引起呼吸系统疾病及死亡的机制及对策
  • 批准号:
    10743181
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Utilizing the power of synthetic biology and De Novo design for the overexpression and biochemical stabilization of KCNA6 or Kv1.6 potassium channels in the E. coli expression system
利用合成生物学和 De Novo 设计的力量,实现大肠杆菌表达系统中 KCNA6 或 Kv1.6 钾通道的过度表达和生化稳定
  • 批准号:
    10666856
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Photo-Fragmentation Methods for Single-Molecule Protein Sequencing by Nanopore Mass Spectrometry
纳米孔质谱单分子蛋白质测序的光断裂方法
  • 批准号:
    10644378
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
A Chicago Biomedical Consortium Hub of Innovative Technologies for Entrepreneurship and Science (CBC - HITES)
芝加哥生物医学联盟创业与科学创新技术中心 (CBC - HITES)
  • 批准号:
    10783500
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
Biosynthesis of marine terpenoid natural products
海洋萜类天然产物的生物合成
  • 批准号:
    10737210
  • 财政年份:
    2023
  • 资助金额:
    $ 66.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了